We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 20, 2021

Differing Outcomes Between Codon 12/13 and Codon 61 NRAS-Mutated Cancers in Patients With NRAS-Mutated Tumors Treated With Binimetinib

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients With NRAS-Mutated Tumors
Clin. Cancer Res 2021 Feb 26;[EPub Ahead of Print], JM Cleary, VX Wang, RS Heist, S Kopetz, EP Mitchell, J Zweibel, KS Kapner, HX Chen, S Li, RJ Gray, LM McShane, L Rubinstein, D Patton, F Meric-Bernstam, MS Dillmon, PM Williams, SR Hamilton, B Conley, A Aguirre, PJ O'Dwyer, LN Harris, CL Arteaga, AP Chen, KT Flaherty

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading